Detalle Publicación

ARTÍCULO
Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial
Autores: Sorio, Roberto; Roemer-Becuwe, Celia; Hilpert, Felix; Gibbs, Emma; Garcia, Yolanda; Kaern, Janne; Huizing, Manon; Witteveen, Petronella; Zagouri, Flora; Coeffic, David; Luck, Hans-Joachim; González Martín, Antonio; Kristensen, Gunnar; Levache, Charles-Briac; Lee, Chee Khoon; Gebski, Val; Pujade-Lauraine, Eric; AURELIA Investigators
Título de la revista: GYNECOLOGIC ONCOLOGY
ISSN: 1095-6859
Volumen: 144
Número: 1
Páginas: 65-71
Fecha de publicación: 2017
Resumen:
In exploratory analyses, PFS and response rate improvement with bevacizumab were consistent in older and younger patients. Grade¿3 hypertension was more common in elderly bevacizumab-treated patients; careful monitoring is recommended. Overall, bevacizumab-containing therapy was well tolerated in a selected population aged ¿65years, suggesting a favourable benefit:risk profile. However, geriatric assessments are needed to improve selection of elderly patients potentially gaining symptom and quality of life improvements from bevacizumab-containing therapy